



BROKERAGE FOR HEALTH

September 3-4 2018, Oslo



Session 1 Better health and care



Comprehensive introduction of P4 medicine: evidence based innovative approaches

Nadiya Boyko

R&D Centre for Molecular Microbiology Mucosal Immunology, National
University & Ediens LLC,
Uzhhorod, Ukraine



Project idea

We propose:

- 1) Implementation of IT algorithm for patients stratification based on clinically proved data of **individual microbiome differences connected with immune response** of patients as recognized biomarkers with NCD and other diseases;
- 2) Apply our unique model of **in vitro cultivated donors' derived human dendritic cells** for prediction of the drugs efficacy by detection of its early programming pro – or anti-inflammatory influence and use the individual changes of microbiome for the same aim;
- 3) Enable application contemporary personalized medicine - novel pharmabiotics (immunobiotics) - which are **patient oriented** and **nosology specific**

We require:

- 1) The access to comprehensive and validated global clinical data (i.e. The Platform for Next Generation Clinical Research 'ACES health') and Hospitals
- 2) IT scaling-up expertise and iCloud;
- 3) Social experts to update and adapt societies with novel solutions and lobbyist to uptake it on governmental level



Companies expertises



R&D Centre for Molecular Microbiology Mucosal Immunology (University):

- Rational standardized patient-centred *earlier biomarkers based diagnostic*;
- Branded *personalised pharmabiotics (immunobiotics)* – Individual and nosology specific – for treatment of infectious diseases;
- Numerous interconnected *databases*; conducting *clinical trials* and *cohort studies*;
- Directed modulation of human microbiome

Ediens LLC (SME):

- Commercialization of innovative research produced by RDC MMMI team;
- Owner of beta-version of the IT software developed with aim of early diagnostic and for the screening of pharmabiotics / nutrition / medications for prognostic prevention and treatment of NCDs and other diseases, based on directed correction of the microbiome and correlated biomarkers;
- Involved into manufacturing (with core partners) of novel pharmabiotics

Topic

SC1-BHC-19-2019: Implementation research for maternal and child health (deadline: Apr 16, 2019)

SC1-BHC-25-2019: Demonstration pilots for implementation of personalised medicine in health care (deadline: Apr 16, 2019)

Keywords

- human microbiome, patients stratification, P4 medicine
- databases, biomarkers, NCD, IT instrument, pharmabiotics
 - cohort study, clinical trials

Topic

Available relevant partners:

1. Consorci Sanitari de Terrassa (Spain, Catalonia)
2. University College London (UK)
3. AiDEAS (Estonia)
4. AbAcus (Italy)
5. Eurecat (Spain)

Requested partners with the following expertise:

1. Hospitals with wide internal network for piloting and cohort studies
2. Partners with strong experience for social research
3. Companies whose dealing with legislation issues
4. IT organizations with iCloud solutions
5. P4 association ICPeMed



Contact details

Thank you!

Nadiya Boyko

prof., Director of RDC MMMI, co-founder of Ediens LLC,

E-mail: nadiya.boyko@gmail.com

<http://www.uzhnu.edu.ua/en/>

<https://www.ediens.info/>